Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 6 days ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 8 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 11 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 11 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - 11 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 12 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 12 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
2	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
3	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
4	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 9 days ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma takes aim at a wily foe — the Epstein-Barr virus - 13 days ago 2024 PharmaVoice 100s: Rare Disease Warriors - 19 days ago 2024 PharmaVoice 100s: Trailblazers - about 1 month ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - about 2 months ago Who’s winning in biotech’s tight market? - 2 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 2 months ago What pharma has learned from AI - 4 months ago Up-and-comers look for an edge in the bustling ADC field - 5 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 5 months ago Where competition is heating up in pharma - 6 months ago The biggest questions hanging over pharma in 2024 - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 10 months ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago
6	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	WuXi looks to sell assets as BIOSECURE Act looms - about 1 month ago
7	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - 2 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	BioMarin’s big day today - 2 months ago
9	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 3 months ago The biotech news you missed this week - 4 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 11 months ago FDA chastens pet companies over antibiotics - 11 months ago Novartis is building a new radioligand plant in China - 12 months ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 3 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 3 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 5 months ago 4 offbeat biotechs making a splash in the life sciences - 7 months ago These biotech hotspots are ripe for IPOs - 8 months ago

Journalists covering biopharma